A charitable institution under Section 88 of the Inland Revenue Ordinance, Hong Kong Special Administrative Region
|18/01/2023||Peter Y. M. Woo, Tiffany H. P. Law, Kelsey K. Y. Lee, Joyce S. W. Chow, Lai-Fung Li, Sarah S. N. Lau, Tony K. T. Chan, Jason M. K. Ho, Michael W. Y. Lee, Danny T. M. Chan & Wai-Sang Poon||Repeat resection for recurrent glioblastoma in the temozolomide era: a real-world multi-centre study Repeat resection for recurrent glioblastoma in the temozolomide era: a real-world multi-centre study||https://doi.org/10.1080/02688697.2023.2167931||-|
|10/09/2022||Peter Y M Woo, Stephen Yau, Tai-Chung Lam, Jenny K S Pu, Lai-Fung Li, Louisa C Y Lui, Danny T M Chan, Herbert H F Loong, Michael W Y Lee, Rebecca Yeung, Carol C H Kwok, Siu-Kie Au, Tze-Ching Tan, Amanda N C Kan, Tony K T Chan, Calvin H K Mak, Henry K F Mak, Jason M K Ho, Ka-Man Cheung, Teresa P K Tse, Sarah S N Lau, Joyce S W Chow, Aya El-Helali, Ho-Keung Ng, Wai-Sang Poon||Patterns of Care and Survival of Chinese Glioblastoma Patients in the Temozolomide Era: A Hong Kong Population-Level Analysis over a 14-year Period||http://dx.doi.org/10.1093/nop/npac069||-|
|11/07/2012||Jenny K.S. Pu, Gloria K.B. Ng, Gilberto K.K. Leung, Chi-Keung Wong||One-year review of the incidence of brain tumours in Hong Kong Chinese patients as part of the Hong Kong Brain and Spinal Tumours Registry||10.1111/j.1744-1633.2012.00616.x||-|
|02/12/2016||Danny TM Chan, FRCS, FHKAM (Surgery); Sonia YP Hsieh, MB, BS, MSc; Claire KY Lau, MSc; Michael KM Kam, FRCR, FHKAM (Radiology); Herbert HF Loong, MB, BS, MRCP (UK); WK Tsang, FRCR, FHKAM (Radiology); Darren MC Poon, FRCR, FHKAM (Radiology); WS Poon, FRCS, FHKAM (Surgery)||Ten-year review of survival and management of malignant glioma in Hong Kong||10.12809/hkmj164879||-|
|17/04/2018||Peter Woo, Jason Ho, SandyLam, Eric Ma, Danny Chan, Wai-Kei Wong, Calvin Mak, Michael Lee, Sui-To Wong, Kwong-Yau Chan, Wai-Sang Poon||A Comparative Analysis of the Usefulness of Survival Prediction Models for Patients with Glioblastoma in the Temozolomide Era: The Importance of Methylguanine Methyltransferase Promoter Methylation, Extent of Resection, and Subventricular Zone Location||10.1016/j.wneu.2018.04.059||-|
|24/04/2020||Herbert H-F.Loong, Aliss MWong, Danny T-M.Chand, Maggie S-H.Cheung, Chit Chow, Xiaofan Ding, Aden K-Y.Chan, Paul A.Johnston, James Y-W.Lau, Wai SangPoon, Nathalie Wong||Patient-derived tumor organoid predicts drugs response in glioblastoma: A step forward in personalized cancer therapy?||10.1016/j.jocn.2020.04.107||-|
|27/06/2019||Peter Y. M. Woo, Yi Li, Anna H. Y. Chan, Stephanie C. P. Ng, Herbert H. F. Loong, Danny T. M. Chan, George K. C. Wong, Wai-Sang Poon||A multifaceted review of temozolomide resistance mechanisms in glioblastoma beyond O-6-methylguanine-DNA methyltransferase||10.21037/apm.2018.10.02||-|
|17/09/2018||Tai Chung Lam, Yolanda Tseng||Defining the radiation oncologist’s role in palliative care and radiotherapy||10.21037/apm.2018.10.02||-|
|15/05/2017||Tai-Chung Lam, Arjun Sahgal, Simon S. Lo, Eric L. Chang||An update on radiation therapy for brain metastases||10.21037/cco.2017.06.02||-|
|17/10/2020||Ho-Keung Ng, Aden Ka-Yin Chan, Nim-Chi Amanda Kan, Dennis Tak-Loi Ku, Danny Tat-Ming Chan, Kay Ka-Wai Li||To do genomics or not do? This is the question||10.4103/glioma.glioma_22_20||-|
|08-08-2021||Patrick Y Wen, Roger J Packer||The 2021 WHO Classification of Tumors of the Central Nervous System: clinical implications||10.1093/neuonc/noab120||-|
Dr. Stephen Yau (丘德芬醫生)
Dr. Rebecca Yeung(楊美雲醫生)
Dr. Carol CH Kwok(郭子熹醫生)
Prof. Herbert HF Loong(龍浩鋒教授)
Dr. SK Au(區兆基醫生)
Dr. Ken KM Cheung(張嘉文醫生)
Dr. Louisa CY Lui(呂卓如醫生)
Dr. TC Tan(陳智勤醫生)
Dr. Michael WY Lee(李永恩醫生)
Dr. Tony KT Chan(陳甘棠醫生)
Dr. LF Li(李禮峰醫生)
Dr. Amanda NC Kan(簡念慈醫生)
Dr Jenny KS Pu(浦勤孫醫生)
Dr. TC Lam(林泰忠醫生)
Dr. Henry KF Mak(麥嘉豐醫生)
Dr. Jason Ho(何文傑醫生)
- A Board of 15 people from different backgrounds and professions. The role is to overlook the running of the society, the projects/events initiated by the Society and financial expenses.
- Council: 1 President, 2 Vice Presidents, 1 Treasurer, 1 Secretary and 10 Council Members
- Member: any healthcare professional interested in Neurooncology
Any medical practitioner normally residing in Hong Kong who has an interest in tumours of the nervous system shall be eligible for application to be admitted as a full member of the Society upon the written recommendation of two full members of the Society.
All applications for full membership are subject to approval by the Council. Full member has voting right and shall be eligible for election to office.
Any person who is involved in the study or care of patients with tumours of the nervous system but is not qualified to be registered as a medical practitioner or not normally residing in Hong Kong shall be eligible for application to be admitted as an associate member of the Society upon the written recommendation of two full members of the Society, or one full member and one associate member.
All applications are subject to approval by the Council. Associate members shall have no voting rights and shall not be eligible for election to office.
The Council may recommend at the annual General Meeting distinguished persons in the field of tumours of the nervous system or persons or corporations who have in the opinion of the Council made great contributions to the Society to become honorary members.
Honorary members shall have no voting rights and shall not be eligible for election to office.
APPLICATION FOR MEMBERSHIP
Asian Society for Neuro-Oncology (ASNO) 亞洲神經腫瘤學會
Chinese Society of Neuro-Oncology (CSNO) 中国抗癌协会神经肿瘤专业委员会
Hong Kong Neurosurgical Society 香港神經外科學會
Hong Kong Society of Medical Oncology 香港臨床腫瘤科學會
Hong Kong Precision Oncology Society 香港精準腫瘤醫學會
The Hong Kong Cancer Therapy Society 香港腫瘤化療學會
Hong Kong Anti-Cancer Society 香港防癌會
Hong Kong Society of Palliative Medicine 香港紓緩醫學學會
Hong Kong Palliative Nursing Association 香港紓緩護理學會